Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat type of misinformation will be corrected first by pharmaceutical companies by end of 2024?
Unapproved drug uses • 25%
Side effects • 25%
Efficacy claims • 25%
Other • 25%
Official announcements or social media posts by pharmaceutical companies
FDA Issues New Guidance to Help Pharma Correct Misinformation on Social Media
Jul 9, 2024, 01:02 PM
The US FDA has issued new draft guidance aimed at helping pharmaceutical companies correct misinformation, particularly on social media. This guidance includes updates from 2014 and introduces terms like 'influencer' to address the growing spread of rumors. FDA Commissioner Dr. Robert Califf emphasized the need for the industry to 'promptly and proactively' tackle misinformation. The guidance allows prescription drug and medical device makers to directly correct claims made by social media influencers or other third parties about unapproved uses of medical products. Additionally, the FDA has created a new safe harbor to enable pharma companies to correct misinformation without violating advertising and promotion regulations. This move is part of a broader effort to ensure accurate information about medical products and to address false claims, such as those suggesting that lipid-lowering drugs cause Alzheimer’s. The FDA also advised manufacturers to pay attention to data received from CROs.
View original story
Increase • 25%
Decrease • 25%
No significant change • 25%
Varied across platforms • 25%
Individual actors • 25%
Organized group • 25%
Foreign government • 25%
Other • 25%
Trump Supporters • 25%
Non-Trump Supporters • 25%
Mixed • 25%
No Legal Actions • 25%
None • 25%
1-10 cases • 25%
11-50 cases • 25%
More than 50 cases • 25%
Acknowledge and propose further studies • 25%
Deny correlation and defend vaccine safety • 25%
Announce new vaccine formulations • 25%
No official response • 25%
Price caps • 25%
Transparency requirements • 25%
Market share limits • 25%
No action • 25%
Russia Today • 25%
Other foreign entity • 25%
Domestic misinformation source • 25%
No clear source identified • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
5 or more companies • 25%
Statement published without issues • 25%
Statement published with errors • 25%
Statement not published • 25%
Statement delayed • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Moderna • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%